Leading biotech company awarded prestigious Innovate UK grant to expand search for rare disease therapies
Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease. TUBB4A-related leukodystrophies are a group of rare neurodegenerative diseases primarily affecting ...
Source: pharmiweb.com